Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed immune thrombocytopenic (IT) Platelet count less than 30,000/mm3 on two occasions. Platelets \>30000/mm3 with bleeding.~* Less than seven days taking corticosteroids~* Normal to increased numbers of megakaryocytes on bone marrow examination in patients ≥ 60 years~* Subject is ≥ 18 years~* Subject has signed and dated written informed consent.~* No sepsis or fever~* No active infection requiring therapy~* No active chronic viral infection~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion Criteria:~* Performance status above or equal to 2.~* Previous treatment with eltrombopag~* Immunosuppressive treatment within the last month~* Previous splenectomy~* Presence of malignant haematological disease~* Connective tissue disease~* Autoimmune hemolytic anemia~* Pregnancy and lactation~* Not willing to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Eltrombopag and dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).